MedTrace Logo

New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease

NCT01755377 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 63

Last updated 2016-08-22

No results posted yet for this study

Summary

Chagas disease is endemic to Latin America, and is of emerging importance in non-endemic countries because migration of people infected with T. cruzi. Current methods for diagnosis of T. cruzi infection are not ideal. Existing drugs for treatment are very limited, produce severe side-effects, and their effectiveness cannot be properly evaluated. Reliable biomarkers for prognosis, early diagnosis and effectiveness of treatment will be investigated.

Conditions

  • Chagas Disease

Interventions

DRUG

Benznidazole

Sponsors & Collaborators

  • Barcelona Centre for International Health Research

    lead OTHER

Principal Investigators

  • Joaquim Gascón, PhD · Barcelona Centre for International Health Research (CRESIB)

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2016-05-31
Completion
2016-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01755377 on ClinicalTrials.gov